Company intelligence

GLUE

Monte Rosa Therapeutics, Inc. · NASDAQ · Healthcare

Price$14.07-1.75% · −$0.25

Market cap1.19BEquity value

P / E-8.0Trailing ratio

Volume1.17MLatest session

Market data

GLUE price chart

TradingView

Related signals

1 min delayed

Browse public GLUE signals with their source context and measured market impact. Open any signal for its permanent analysis page.

GLUEDec 16, 2025-10.24% since signal

Why Is Monte Rosa Stock Trading Higher Today?

Monte Rosa shared positive interim findings for MRT-2359 in prostate cancer. The study achieved a 100% disease control rate in AR-mutant patients. Next phase study planned to assess efficacy of MRT-2359 with additional inhibitors. Safety profile noted as favorable, primarily mild to moderate adverse effects. GLUE’s stock rose 11.43% following the positive data release.

View signal analysis

GLUEOct 28, 2024-6.58% since signal

This Biotech Stock Has Doubled Its Value Today—Here's Why

Monte Rosa struck a $2.1 billion deal with Novartis. MRT-6160 drug is currently in Phase 1 trials. Upfront payment of $150 million received from Novartis. Shares of Monte Rosa doubled after the announcement. Deal extends Monte Rosa's operational runway for drug pipeline.

View signal analysis

Research